Research ArticleClinical Investigations
Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I
Walter Jentzen, Andreas Bockisch and Marcus Ruhlmann
Journal of Nuclear Medicine June 2015, 56 (6) 832-838; DOI: https://doi.org/10.2967/jnumed.114.153031
Walter Jentzen
Klinik für Nuklearmedizin, Universität Duisburg-Essen, Essen, Germany
Andreas Bockisch
Klinik für Nuklearmedizin, Universität Duisburg-Essen, Essen, Germany
Marcus Ruhlmann
Klinik für Nuklearmedizin, Universität Duisburg-Essen, Essen, Germany
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 56, Issue 6
June 1, 2015
Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I
Walter Jentzen, Andreas Bockisch, Marcus Ruhlmann
Journal of Nuclear Medicine Jun 2015, 56 (6) 832-838; DOI: 10.2967/jnumed.114.153031
Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I
Walter Jentzen, Andreas Bockisch, Marcus Ruhlmann
Journal of Nuclear Medicine Jun 2015, 56 (6) 832-838; DOI: 10.2967/jnumed.114.153031
Jump to section
Related Articles
Cited By...
- Efficacy and Safety of 124I-MIBG Dosimetry-Guided High-Activity 131I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma
- Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma
- Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
- Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities
- Alternative Means of Estimating 131I Maximum Permissible Activity to Treat Thyroid Cancer
- Iodine Symporter Targeting with 124I/131I Theranostics
- Fixed 3.7-GBq 131I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History
- 124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer
- High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases